Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

↓ Direkt till sidans innehåll
↓ Direkt till sidans sekundära innehåll (sidomenyn)

Sökning: L773:0960 314X OR L773:1473 561X > Polymorphisms of NA...

Wadelius, MiaUppsala universitet,Klinisk farmakogenomik och osteoporos (författare)

Polymorphisms of NAT2 in relation to sulphasalazine-induced agranulocytosis

Artikel/kapitelEngelska2000

Förlag, utgivningsår, omfång ...

2000
printrdacarrier

Nummerbeteckningar

LIBRIS-ID:oai:DiVA.org:uu-54712
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-54712URI

Kompletterande språkuppgifter

Språk:engelska
Sammanfattning på:engelska

Ingår i deldatabas

SwePubSwePub

Klassifikation

Ämneskategori:ref swepub-contenttype
Ämneskategori:art swepub-publicationtype

Anmärkningar

Agranulocytosis is a rare, but serious adverse reaction to sulphasalazine. The polymorphic enzyme N-acetyltransferase 2 (NAT2) plays an important role in the metabolism of sulphasalazine. This study was conducted to analyse whether the risk of sulphasalazine-induced agranulocytosis is increased in slow acetylators. Patients were treated for inflammatory disease, mostly joint disease, with a mean dose of 2 g sulphasalazine daily. Thirty-nine patients reacted with agranulocytosis, while 75 patients had been treated for a minimum of 3 months without haematological side-effects. A population-based control panel of 448 individuals was used for comparison. All subjects were genotyped for NAT2 by polymerase chain reaction followed by restriction enzyme digestion. The six most common allelic variants were analysed: NAT2*4, NAT2*5A, NAT2*5B, NAT2*5C, NAT2*6 and NAT2*7. The proportion of slow acetylators was significantly higher in patients with sulphasalazine-induced agranulocytosis (69%) and population-based controls (64%) compared to patients who tolerated sulphasalazine (45%); odds ratio 2.71 [95% confidence interval (CI) 1.20; 6.15], P = 0.015, and odds ratio 2.17 (95% CI 1.32; 3.56), P = 0.002, respectively. Patients who developed agranulocytosis did not differ from population-based control subjects in the frequency of slow acetylators; odds ratio 1.25 (95% CI 0.62; 2.53), P = 0.535. The risk of agranulocytosis did not appear to be increased in slow acetylators, provided that the difference compared with sulphasalazine-treated control subjects was not due to a predominance of fast acetylators among patients with inflammatory joint disease. Instead, selection bias was suspected since more slow acetylators may have discontinued sulphasalazine therapy because of drug-intolerance.

Ämnesord och genrebeteckningar

sulfasalazine
agranulocytosis
NAT2
pharmacogenetics
MEDICINE
MEDICIN

Biuppslag (personer, institutioner, konferenser, titlar ...)

Stjernberg, ElisabethUppsala universitet,Klinisk farmakologi (författare)
Wiholm, Bengt-Erik (författare)
Rane, AndersUppsala universitet,Institutionen för medicinska vetenskaper,Klinisk farmakologi, A Rane (författare)
Uppsala universitetKlinisk farmakogenomik och osteoporos (creator_code:org_t)

Sammanhörande titlar

Ingår i:Pharmacogenetics10:1, s. 35-410960-314X1473-561X

Internetlänk

https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-54712

Hitta via bibliotek

Pharmacogenetics (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...: Wadelius, Mia; Stjernberg, Elis ...; Wiholm, Bengt-Er ...; Rane, Anders

Artiklar i publikationen: Pharmacogenetics

Av lärosätet: Uppsala universitet

Sök utanför SwePub

Sök vidare i:: Google; Google Book Search; Google Scholar

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

LIBRIS.kb.se